The QOLIXANE study is a prospective, non‐interventional, multicenter sub‐study of the Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer (PARAGON) registry, which evaluated QoL in patients with metastatic pancreatic cancer receiving first‐line gemcitabine and nab‐paclitaxel chemotherapy in real‐life setting. Read more . . . .
Few data exists on health‐related quality of life (QoL) in patients with metastatic pancreatic cancer receiving first‐line chemotherapy 1.